NCT00403130 - Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

November 30, 2012

Conditions

Breast CancerMetastatic Breast Cancer

Interventions

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles

DRUG

Paclitaxel

Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles

DRUG

Bevacizumab

Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles

Trial Locations (1)

Stanford University School of Medicine, Stanford